News

AmMax to participate in Cowen Conference on March 3rd. Read More>

AmMax Bio, Inc.

Slogan 2020 AmMax white 3 lines.png
September 12, 2022
AmMax Bio Announces Presentation of Phase 2 PK/PD Data of...

REDWOOD CITY, Calif. Sep. 12, 2022 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, including...

September 7, 2022
AmMax Bio Announces AMB-05X Granted FDA Fast Track Designation...

REDWOOD CITY, Calif. Sep. 7, 2022 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, including...

shutterstock_1174276207_edited_edited.jp
 
shutterstock_724957504_edited.jpg

ABOUT US​

Launched in March 2020 out of a partnership between LifeMax and Amgen, AmMax Bio, Inc. (“AmMax”) is a privately held, clinical stage biotech company focused on unlocking the therapeutic potential of the CSF1R platform (“colony stimulating factor 1 receptor”) to address diseases with significant unmet medical needs and sizable market potential. We have two clinical stage programs ready to enter Phase 2 studies.

NEWS

shutterstock_1682600770_edited.jpg

R&D

AmMax has established a robust pipeline targeting CSF1R. In addition to tenosynovial giant cell tumor wherein an overexpression of CSF1 drives the pathogenesis, AmMax’s pipeline addresses a number of other diseases with critical unmet medical needs, such as idiopathic pulmonary fibrosis, retinal disease (nAMD/DME) and polycystic kidney diseases, by leveraging the anti-inflammatory, anti-fibrotic and anti-neovascular technology platform targeting CSF1R.

News

AmMax Bio Announces Presentation at ESMO Congress 2022...
Read More>

July 25, 2022 
AmMax Bio Announces the Appointment of Dorothy Nguyen, M.D. ...

REDWOOD CITY, Calif. July 25, 2022 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, including...